The RET proto-oncogene: a molecular therapeutic target in thyroid cancer. - Wikidata - wikimedia - TriplyDB

The RET proto-oncogene: a molecular therapeutic target in thyroid cancer.

The RET proto-oncogene: a molecular therapeutic target in thyroid cancer.

http://www.wikidata.org/entity/Q36072495

about

Rap1GAP interacts with RET and suppresses GDNF-induced neurite outgrowth Interaction of SH2-Bbeta with RET is involved in signaling of GDNF-induced neurite outgrowth Solution structure of all parallel G-quadruplex formed by the oncogene RET promoter sequence Structural insights into FRS2α PTB domain recognition by neurotrophin receptor TrkB Modulatory role of phospholipase D in the activation of signal transducer and activator of transcription (STAT)-3 by thyroid oncogenic kinase RET/PTC Sorafenib cardiotoxicity increases mortality after myocardial infarction.Thyroid cancer: current molecular perspectives.Formation of pseudosymmetrical G-quadruplex and i-motif structures in the proximal promoter region of the RET oncogene.Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement.Selective repression of RET proto-oncogene in medullary thyroid carcinoma by a natural alkaloid berberine.Molecular classification and biomarker discovery in papillary thyroid carcinoma.RET receptor signaling: dysfunction in thyroid cancer and Hirschsprung's disease.Prognostic molecular biomarkers for cutaneous malignant melanoma Neurotrophic factor receptor RET: structure, cell biology, and inherited diseases.Regulation of growth factor signaling by FRS2 family docking/scaffold adaptor proteins.Functional RET G691S polymorphism in cutaneous malignant melanoma.Deletion of Frs2alpha from the ureteric epithelium causes renal hypoplasia The FRS2 family of docking/scaffolding adaptor proteins as therapeutic targets of cancer treatment.Medullary thyroid carcinoma: a 25-year perspective.Radiation signatures in childhood thyroid cancers after the Chernobyl accident: possible roles of radiation in carcinogenesis.Sphingosine kinase 1/S1P pathway involvement in the GDNF-induced GAP43 transcription.Downregulation of TRIM27 expression inhibits the proliferation of ovarian cancer cells in vitro and in vivo.Overexpression of miR-218 inhibits hepatocellular carcinoma cell growth through RET.Expression variability and function of the RET gene in adult peripheral blood mononuclear cells.Structural modification of an EGFR inhibitor that showed weak off-target activity against RET leading to the discovery of a potent RET inhibitor.Hedgehog signaling in human medullary thyroid carcinoma: a novel signaling pathway.Targeting RET to induce medullary thyroid cancer cell apoptosis: an antagonistic interplay between PI3K/Akt and p38MAPK/caspase-8 pathways.Glial cell line-derived neurotrophic factor: characterization of mammalian posttranslational modifications.Combination of RET siRNA and irinotecan inhibited the growth of medullary thyroid carcinoma TT cells and xenografts via apoptosis.Sprouty2 regulates growth and differentiation of human neuroblastoma cells through RET tyrosine kinase.The mouse soluble GFRalpha4 receptor activates RET independently of its ligand persephin.N-Myc is a downstream target of RET signaling and is required for transcriptional regulation of p18(Ink4c) by the transforming mutant RET(C634R).KIF5B-RET fusion kinase promotes cell growth by multilevel activation of STAT3 in lung cancer.Simultaneous downregulation of CDK inhibitors p18(Ink4c) and p27(Kip1) is required for MEN2A-RET-mediated mitogenesis.Prognostic and predictive markers in medullary thyroid carcinoma.An evaluation and recommendation of the optimal methodologies to detect RET gene rearrangements in papillary thyroid carcinoma.Targeted Therapy for Medullary Thyroid Cancer: A Review.Pathogenesis of differentiated thyroid cancer (papillary and follicular)Drug resistance profiles of mutations in the RET kinase domain

P2860

Q24301386-40762FBB-1D83-4F5A-A292-1CF15476E81F Q24311524-A697B5A0-7FA4-4752-9072-6602D5CA7EA6 Q27667674-29FA437C-175E-4D88-AFA5-6C55DA7E82B3 Q27681484-65C15BB9-49F4-4784-A86D-47602B5299D6 Q33337251-07073C92-9138-4D3E-90B1-231F1B2F11B7 Q33681995-938774CE-9542-439B-94FB-B515A3BD3022 Q33760910-89CB9D49-2D85-492D-9B7E-BF90E68F7F67 Q34005475-96DA97C1-0A3A-41FF-99A6-C6C0F6AD8779 Q35570953-B3A29A00-56C0-4019-B1A2-4ACD8B8307B4 Q35755355-37D78836-7116-493E-AE71-EF9959132296 Q36299916-73E504FE-7DD6-414E-973A-C14783985D22 Q36458528-442D7EA3-0766-4683-9F42-8534F7F327F6 Q36905877-232BEE23-20CA-4823-90DC-A85AF0ACF468 Q36970334-54831CD6-160C-4DC3-A89F-A13BD3729FC0 Q37152909-95770E5A-FD59-4954-9DA5-63A356B64320 Q37334690-04328B7C-7B60-4EC8-BFAB-762B27D35166 Q37430764-1082E52C-A20D-4978-B681-845D288C031E Q37489930-EB2EAB88-4BA2-4FC7-B5FD-01C5CF7C0459 Q38171726-EFA4F123-2F2B-4FEA-A9A9-E76E79C32650 Q38284743-32729602-A3E6-499F-BBF0-E92C86F04D60 Q38333309-78259458-4F8A-4238-8235-95447825CD6C Q38819559-0C586992-C304-4B0D-8861-46DE551C9164 Q38942388-53F07991-88FE-4E1A-9127-7A8EA87096BE Q39000564-096C59CD-62D0-4983-BF51-E2A431FCF5E8 Q39025184-EC943796-5FBE-4736-90E4-0F43077516E6 Q39194433-9D207D30-49C5-480D-A028-13ED73A0DC62 Q39208774-B84E0205-3525-44CA-A7E6-82647BBE3673 Q39213096-7FC8BAAC-5AB0-442F-880B-2FA3301C919D Q39668289-7722A329-0C2C-4082-9C93-A79693700FA1 Q40153841-4FCFFF19-18D7-40E6-A657-4873445AA70D Q40184745-881FC728-19D8-4CAB-AA44-FA93EC0004FC Q41132441-0D707569-FD0E-4E28-BDBA-02B80E3F76BF Q42118166-D58351DC-FE52-4791-A4BD-C5009B6713A6 Q42796164-99880283-143B-4E4A-A6CA-954E4BFBF521 Q43891433-5C17B856-E437-40FE-8543-5B23B80D4699 Q44116793-A21D646F-FEBA-48C3-8EB9-669B4E9240BB Q49328959-006CC7C2-887C-4701-9340-D7415336091A Q56568567-0F5D8777-DE58-4B63-A98F-03138CA1789E Q58044610-9B7AB059-A173-41A6-8B33-02A0747E01F4

P2860

The RET proto-oncogene: a molecular therapeutic target in thyroid cancer.

http://www.wikidata.org/entity/Q36072495

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

The RET proto-oncogene: a molecular therapeutic target in thyroid cancer.

@ast

The RET proto-oncogene: a molecular therapeutic target in thyroid cancer.

@en

type

label

The RET proto-oncogene: a molecular therapeutic target in thyroid cancer.

@ast

The RET proto-oncogene: a molecular therapeutic target in thyroid cancer.

@en

prefLabel

The RET proto-oncogene: a molecular therapeutic target in thyroid cancer.

@ast

The RET proto-oncogene: a molecular therapeutic target in thyroid cancer.

@en

P1433

Q36072495-429D1B3F-A214-4086-90BD-182743FFAD86

P1476

Q36072495-36AE4362-5413-4A31-8B2C-F163DA42C618

P2093

Q36072495-375ED9CD-59AF-41D1-BF89-9E2B15759952

Q36072495-476070D2-E6DB-4961-A2E5-33716FBD385E

Q36072495-B0357B3C-7C4C-40A8-A487-42CCE0746096

Q36072495-BCCAB9A1-BE4E-44B8-ABC8-D4EB7DCB96E1

Q36072495-DD7A0705-6071-404C-B9E1-1942A01FB60F

Q36072495-DF8211FB-DE39-43EE-A133-1D0CBBFE0D62

Q36072495-F7F9F422-9D7F-4ECF-B368-A2340415AE1D

P2860

Q36072495-20A9D9C4-B1DA-4F3B-BF3E-05AD45AA158B

Q36072495-25780CC2-CC3A-41B1-AB55-F6769D8210C2

Q36072495-3935F753-3DE5-4BEC-8185-CA1A20AF3814

Q36072495-44C8D6DB-ADEC-48D3-BF40-F39827DD0EB1

Q36072495-45AB156F-C612-48D7-967A-A68F47C409D3

Q36072495-48FFF19B-1E8D-4487-996A-1D5931FEF801

Q36072495-51B6CDA1-641A-48A6-9C1C-33F78EA93078

Q36072495-558D2780-A533-459D-8CC0-83A8A7D973A8

Q36072495-56CB850D-8E6C-4F0F-ADB7-688D81E665C4

Q36072495-5DD35067-4D7D-4AAA-A148-EB71A941C279

P304

Q36072495-A1EB3099-4BDB-46BC-A7FF-A8FB7478AEF2

P31

Q36072495-7B3C91C8-4F49-484D-9F8E-7A4A7091133D

P356

Q36072495-74AF766B-B131-4571-9D42-695463B09FDC

P433

Q36072495-031026CA-BB5F-45A9-A902-EA35791A8AAD

P478

Q36072495-9766244A-73CF-46C7-A376-DD916F1C91FD

P577

Q36072495-DC446CB5-DF1C-47F8-A3A7-FA37E06BAC28

P5875

Q36072495-867FA105-1D12-4652-A9A2-8BA8DE248A53

P698

Q36072495-BF49093F-774F-4E3E-9389-FF681762AF49

P356

J.1349-7006.2005.00023.X

P1433

P1476

The RET proto-oncogene: a molecular therapeutic target in thyroid cancer.

@en

P2093

Kumi Kawai

http://www.w3.org/2001/XMLSchema#string

Masahide Takahashi

http://www.w3.org/2001/XMLSchema#string

Masatoshi Ichihara

http://www.w3.org/2001/XMLSchema#string

Mayumi Jijiwa

http://www.w3.org/2001/XMLSchema#string

Naoya Asai

http://www.w3.org/2001/XMLSchema#string

Yoshiki Murakumo

http://www.w3.org/2001/XMLSchema#string

Yoshinori Kodama

http://www.w3.org/2001/XMLSchema#string

P2860

MEN2A-RET-induced cellular transformation by activation of STAT3

The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma

Defects in enteric innervation and kidney development in mice lacking GDNF

GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF

Central role of the threonine residue within the p+1 loop of receptor tyrosine kinase in STAT3 constitutive phosphorylation in metastatic cancer cells

ret transforming gene encodes a fusion protein homologous to tyrosine kinases

Role of Dok1 in cell signaling mediated by RET tyrosine kinase

The GDNF family: signalling, biological functions and therapeutic value

Activation of a novel human transforming gene, ret, by DNA rearrangement

The Ret receptor protein tyrosine kinase associates with the SH2-containing adapter protein Grb10

P304

143-148

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1349-7006.2005.00023.X

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

96

http://www.w3.org/2001/XMLSchema#string

P577

2005-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7962499

http://www.w3.org/2001/XMLSchema#string

P698

15771616

http://www.w3.org/2001/XMLSchema#string